{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:27:08Z","timestamp":1787009228086,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tinea corporis and tinea cruris are common dermatophyte infections of increasing public health concern, yet national US data are limited. We estimated incidence, risk factors, and diagnostic and treatment practices among a large Medicaid-insured outpatient cohort. Among \u223c6\u2009800\u2009000 enrollees, 54\u2009108 were diagnosed with tinea corporis (79.1\/10\u2009000 person-years) and 8386 with tinea cruris (12.2\/10\u2009000 person-years). Tinea corporis primarily affected young children and Black patients, while tinea cruris was prevalent among middle-aged men. Overall, &amp;lt;10% received diagnostic testing, and 7%\u201310% were treated with combination antifungal-corticosteroid products, highlighting the opportunities to increase testing and promote judicious antifungal use amid emerging resistance.<\/jats:p>","DOI":"10.1093\/mmy\/myaf117","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:24:26Z","timestamp":1765887866000},"source":"Crossref","is-referenced-by-count":4,"title":["Tinea corporis and tinea cruris incidence, risk factors, and treatments in a cohort of 6.8 million patients with Medicaid, United States"],"prefix":"10.1093","volume":"64","author":[{"given":"Elizabeth T","family":"Sajewski","sequence":"first","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]},{"name":"Epidemic Intelligence Service, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Benedict","sequence":"additional","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avrom S","family":"Caplan","sequence":"additional","affiliation":[{"name":"NYU Grossman School of Medicine The Ronald O. Perelman Department of Dermatology, , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari R","family":"Lipner","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine Department of Dermatology, , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy A W","family":"Gold","sequence":"additional","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"Suppl 4","key":"2026010810174237600_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1439-0507.2008.01606.x","article-title":"Epidemiological trends in skin mycoses worldwide","volume":"51","author":"Havlickova","year":"2008","journal-title":"Mycoses"},{"key":"2026010810174237600_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jdin.2020.10.003","article-title":"The global, regional, and national burden of fungal skin diseases in 195 countries and territories: a cross-sectional analysis from the Global Burden of Disease Study 2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int."},{"key":"2026010810174237600_bib3","doi-asserted-by":"crossref","first-page":"e4380","DOI":"10.1136\/bmj.e4380","article-title":"The diagnosis and management of tinea","volume":"345","author":"Moriarty","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"2026010810174237600_bib4","first-page":"702","article-title":"Diagnosis and management of tinea infections","volume":"90","author":"Ely","year":"2014","journal-title":"Am Fam Physician"},{"issue":"6","key":"2026010810174237600_bib5","doi-asserted-by":"crossref","first-page":"myaf049","DOI":"10.1093\/mmy\/myaf049","article-title":"Economic burden of fungal diseases in the United States","volume":"63","author":"Benedict","year":"2025","journal-title":"Med Mycol"},{"issue":"2","key":"2026010810174237600_bib6","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1111\/ajd.13191","article-title":"Impact on quality of life in patients with dermatophytosis","volume":"61","author":"Mushtaq","year":"2020","journal-title":"Australas J Dermatol"},{"issue":"9","key":"2026010810174237600_bib7","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1111\/jdv.19217","article-title":"Combatting antifungal resistance: paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis","volume":"37","author":"Gupta","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026010810174237600_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamadermatol.2024.1126","article-title":"Clinical course, antifungal susceptibility, and genomic sequencing of Trichophyton indotineae","volume":"160","author":"Caplan","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2026010810174237600_bib9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0190-9622(03)02117-0","article-title":"Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002","volume":"50","author":"Foster","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2026010810174237600_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1365-4632.2009.04025.x","article-title":"Cutaneous fungal infections in the United States: analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995\u20132004","volume":"48","author":"Panackal","year":"2009","journal-title":"Int J Dermatol"},{"key":"2026010810174237600_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jaad.2024.05.020","article-title":"Current epidemiology of tinea corporis and tinea cruris causative species: analysis of data from a major commercial laboratory, United States","volume":"91","author":"Zarzeka","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2026010810174237600_bib12","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaad.2023.07.1025","article-title":"Racial disparities, risk factors, and clinical management practices for tinea capitis: an observational cohort study among US children with Medicaid","volume":"89","author":"Hennessee","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2026010810174237600_bib13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1542\/peds.111.1.201","article-title":"Persistent and recurrent tinea corporis in children treated with combination antifungal\/corticosteroid agents","volume":"111","author":"Alston","year":"2003","journal-title":"Pediatrics"},{"issue":"1","key":"2026010810174237600_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0190-9622(08)80528-2","article-title":"Double-blind comparison of naftifine cream and clotrimazole\/betamethasone dipropionate cream in the treatment of tinea pedis","volume":"26","author":"Smith","year":"1992","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"2026010810174237600_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/ijp.ijp_930_20","article-title":"Topical antifungal-corticosteroid fixed-drug combinations: need for urgent action","volume":"53","author":"Rana","year":"2021","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"2026010810174237600_bib16","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1017\/ash.2024.435","article-title":"Prescribing of clotrimazole-betamethasone dipropionate, a topical combination corticosteroid-antifungal product, for Medicare part D beneficiaries, United States, 2016\u20132022","volume":"4","author":"Currie","year":"2024","journal-title":"Antimicrob Steward Healthc Epidemiol"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myaf117\/65912663\/myaf117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/64\/1\/myaf117\/65912663\/myaf117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/64\/1\/myaf117\/65912663\/myaf117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:17:49Z","timestamp":1767885469000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myaf117\/8381234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myaf117","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,16]]},"article-number":"myaf117"}}